• 1
    Cleeland CS, Sloan JA; ASCPRO Organizing Group. Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards. J Pain Symptom Manage. 2010;39:1077-1085.
  • 2
    Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106:337-345.
  • 3
    NIH State-of-the-Science Statement on symptom management in cancer: pain, depression, and fatigue. NIH Consens State Sci Statements. 2002;19:1-29.
  • 4
    Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007;68:654-661.
  • 5
    Hutcheson KA, Lewin JS, Barringer DA, et al. Late dysphagia after radiotherapy-based treatment of head and neck cancer. Cancer. 2012;118:5793-5799.
  • 6
    Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007;29:923-931.
  • 7
    Rosenthal DI, Mendoza TR, Chambers MS, et al. The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys. 2008;72:1355-1361.
  • 8
    Gunn GB, Mendoza TR, Fuller CD, et al. High symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study. Head Neck. 2013;35:1490-1498.
  • 9
    Shi Q, Mendoza TR, Gunn GB, Wang XS, Rosenthal DI, Cleeland CS. Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res. 2013;22:2331-2339.
  • 10
    Rosenthal DI, Asper JA, Barker JL Jr, et al. Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head Neck. 2006;28:967-973.
  • 11
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
  • 12
    Murphy BA, Gilbert J, Ridner SH. Systemic and global toxicities of head and neck treatment. Expert Rev Anticancer Ther. 2007;7:1043-1053.
  • 13
    Wang XS, Shi Q, Williams LA, et al. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun. 2010;24:968-974.
  • 14
    Wang XS, Williams LA, Krishnan S, et al. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun. 2012;26:699-705.
  • 15
    Schwartz CE, Bode R, Repucci N, Becker J, Sprangers MA, Fayers PM. The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res. 2006;15:1533-1550.